That spreadsheet clearly shows that looking forward produces amazing financial returns to NEU. And the share price based on that forward looking is just not being applied by the market, brokers, and even many NEU holders on HC. And those large numbers are not very far away. 18months. Maybe less if recruiting in US steps up more quickly in 3-6 months.
I have found info re: EU that pricing for orphan drugs are 20%-30% less than US pricing. So US$262,500 to US$300,000 range may be where it falls. EU has 10 yrs protection against US having 7yrs. So it balances out. If a generic appears. Also several individual countries will still need to be dealt with despite being in Euro zone for the most part. From my understanding. Happy to be wrong though.
I doubt we will see patients being dosed in ROW next year, if they have to go through a heap of regulatory requirements and trials. Which is likely.
Thankyou, I look forward to your future posts.
.
NEU Price at posting:
$13.59 Sentiment: Buy Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)